Jefferies Group Comments on Flex Pharma, Inc.’s FY2017 Earnings (NASDAQ:FLKS)
Flex Pharma, Inc. (NASDAQ:FLKS) – Investment analysts at Jefferies Group reduced their FY2017 earnings per share (EPS) estimates for shares of Flex Pharma in a report released on Wednesday. Jefferies Group analyst M. Andrews now forecasts that the biotechnology company will post earnings of ($2.20) per share for the year, down from their prior forecast of ($2.13). Jefferies Group has a “Buy” rating and a $8.00 price objective on the stock. Jefferies Group also issued estimates for Flex Pharma’s FY2018 earnings at ($1.37) EPS, FY2019 earnings at ($1.54) EPS, FY2020 earnings at ($1.12) EPS and FY2021 earnings at ($0.57) EPS.
Separately, Zacks Investment Research lowered Flex Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 23rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $15.40.
Flex Pharma (FLKS) traded down 2.9946% during trading on Monday, reaching $3.5601. The company had a trading volume of 15,644 shares. The firm has a 50-day moving average of $3.92 and a 200-day moving average of $3.96. Flex Pharma has a 1-year low of $3.01 and a 1-year high of $12.68. The stock’s market capitalization is $60.98 million.
Flex Pharma (NASDAQ:FLKS) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.46 million. Flex Pharma had a negative return on equity of 64.15% and a negative net margin of 2,410.97%.
A number of large investors have recently made changes to their positions in FLKS. LMR Partners LLP acquired a new stake in shares of Flex Pharma during the second quarter worth $104,000. Bank of New York Mellon Corp raised its stake in shares of Flex Pharma by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 42,053 shares of the biotechnology company’s stock worth $185,000 after buying an additional 487 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Flex Pharma during the first quarter worth $223,000. Royce & Associates LP raised its stake in shares of Flex Pharma by 255.1% in the first quarter. Royce & Associates LP now owns 242,200 shares of the biotechnology company’s stock worth $1,066,000 after buying an additional 174,000 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its stake in shares of Flex Pharma by 11.2% in the first quarter. C WorldWide Group Holding A S now owns 278,060 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 28,060 shares in the last quarter. 29.17% of the stock is currently owned by institutional investors.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.